Our objective was to evaluate an open-label. multicenter. single-arm study to appraise whether amrubicin therapy improves patients with refractory small-cell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. https://www.nacrack.com/mega-choice-2005-2006-NISSAN-ALTIMA-Radio-Receiver-AM-FM-stereo-single-CD-Player-G-mega-value/